Phase 1 trial

Watertown, Mass., September 3, 2026 C4 Therapeutics announced that new biomarker data evaluating the immunomodulatory effects of cemsidomide in...

Wellesley Hills, Mass., September 3, 2026 Climb Bio announced positive initial Phase 1 clinical data for CLYM116, its investigational...

ALAMEDA, Calif., August 6, 2026 Vivani Medical, Inc. announced the successful full enrollment and initial dosing of all 20...

BRISBANE, Calif., August 6, 2026 Pacira BioSciences announced the publication of positive two-year Phase 1 clinical trial results for...

WATERTOWN, Mass., August 6, 2026 LifeMine Therapeutics has secured $263 million in financing to accelerate the clinical development of...

WALTHAM, Mass., Aug. 5, 2026 Damora Therapeutics, Inc. has announced the initiation of the global Phase 1/1b CLARITY-101 clinical...

PLYMOUTH MEETING, Pa., August 4, 2026 Harmony Biosciences reported record second-quarter 2026 net revenue of $261.3 million for WAKIX®...

NEW YORK and WALTHAM, Mass., August 4, 2026 Dianthus Therapeutics, Inc. announced the launch of DNTH312, an internally developed...

BRISBANE, Calif., August 4, 2026 Nurix Therapeutics, Inc. announced it has earned a $10 million development milestone payment after...

NEEDHAM, Mass., Aug. 3, 2026 Candel Therapeutics, Inc. announced that new data from its Phase 3 clinical program evaluating...